PRIMARY STUDY

Impact of teneligliptin on oxidative stress and endothelial function in type 2 diabetes patients with chronic kidney disease: a case-control study

Key Findings:  Patients with type 2 diabetes and chronic kidney disease (CKD) already taking sitagliptin were either continued on sitagliptin or switched to teneligliptin. Levels of urinary liver-type fatty acid binding protein (L-FABP) in the teneligliptin were reduced significantly, suggesting its anti-inflammatory, antioxidant, and renal protective properties of teneligliptin.